首页> 外文期刊>Breast Cancer: Targets and Therapy >Multidrug-resistant breast cancer: current perspectives
【24h】

Multidrug-resistant breast cancer: current perspectives

机译:多药耐药性乳腺癌:当前观点

获取原文
           

摘要

Abstract: Breast cancer is the most common cancer in women worldwide, and resistance to the current therapeutics, often concurrently, is an increasing clinical challenge. By understanding the molecular mechanisms behind multidrug-resistant breast cancer, new treatments may be developed. Here we review the recent advances in this understanding, emphasizing the common mechanisms underlying resistance to both targeted therapies, notably tamoxifen and trastuzumab, and traditional chemotherapies. We focus primarily on three molecular mechanisms, the phosphatidylinositide 3-kinase/Akt pathway, the role of microRNAs in gene silencing, and epigenetic alterations affecting gene expression, and discuss how these mechanisms can interact in multidrug resistance. The development of therapeutics targeting these mechanisms is also addressed.
机译:摘要:乳腺癌是全世界女性中最常见的癌症,对当前疗法的耐药性(通常同时存在)是日益严峻的临床挑战。通过了解多重耐药性乳腺癌背后的分子机制,可以开发出新的治疗方法。在这里,我们回顾了这种理解的最新进展,重点介绍了对两种靶向疗法(尤其是他莫昔芬和曲妥珠单抗)以及传统化学疗法的耐药性产生抗性的常见机制。我们主要关注三种分子机制,磷脂酰肌醇3激酶/ Akt途径,microRNA在基因沉默中的作用以及影响基因表达的表观遗传改变,并讨论这些机制如何在多药耐药性中相互作用。还讨论了靶向这些机制的疗法的发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号